Opinion|Videos|November 8, 2024
Impact of Treatment Delays on Patient Outcomes
Author(s)Toby Maher, MD, PhD
Key Takeaways
- Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life.
- Delays in treatment can result in advanced disease stages, reduced treatment efficacy, and increased morbidity.
Toby Maher, MD, PhD, discusses how delays in treatment for idiopathic pulmonary fibrosis (IPF) can significantly worsen patient outcomes and accelerate disease progression, underscoring the critical need for timely intervention.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How does a delay in treatment affect patient outcomes and disease progression?
Advertisement
Related to this article
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5